HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revlon

This article was originally published in The Rose Sheet

Executive Summary

Company has received all of the required lender consents to increase its existing $700 mil. term loan facility by $100 mil. under an amendment to its bank credit agreement dated 2004, Revlon announces July 24. Firm expects to close and fund the amendment July 28, "subject to market and other customary conditions," firm notes. Revlon announced it was seeking an amendment to the credit agreement earlier this month (1"The Rose Sheet" June 26, 2006, In Brief)...

You may also be interested in...



Vital Radiance Efforts Intended To Boost Brand Following Difficult Q2

Revlon is renewing plans for Vital Radiance, focusing resources behind the brand's revised retail format, its most productive products and most effective marketing drivers, the company reported during a preliminary second quarter earnings call July 10

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel